

Docket No.: <u>2629-4005US4</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Attila T. Lorincz, et al.

Group Art Unit:

1634

Serial No.:

09/970,477

Examiner:

Diana B. Johannsen

Filed:

October 4, 2001

For:

ASSESSMENT OF HUMAN PAPILLOMA VIRUS-RELATED DISEASE

<u>INFORMATION DISCLOSURE STATEMENT</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1.	\boxtimes	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
		German patent DE 44457969.3. Please consider the IDS and references, including
		this German patent. (Exhibit A).
2.		For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3.		Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed
		·

919765 v1 EV 622479766 US

4.	\boxtimes	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:					
			37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or				
			37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or				
			37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or				
			37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.				
5.		since in para Allow	e is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement t is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified agraph 4 above but before the mailing date of a final action or a Notice of ance (where there has been no prior final action), and is accompanied by one of trifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.				
6.		it is be paragr	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in aph 4 above but before the mailing date of a final action or a notice of ince (where there has been no prior final action):				
			A check in the amount of \$180.00 is enclosed in payment of the fee.				
			Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.				
7.		it is be action	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issue id is accompanied by:				
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and				
			e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.				
8.		This In	nformation Disclosure Statement is being filed in compliance with:				
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);				

(212) 415-8700 Telephone (212) 415-8701 Facsimile

	b	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).						
	c. 🗌	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.						
9.	I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.							
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.							
10.		This document is accompanied by _ a Search Report _ Communication which was cited in a corresponding _ PCT or _ Foreign counterpart application						
11.	A check in the amount of \$\\$ is enclosed in payment of the fees due under 37 C.F.R. \\$\\$1.17(h) and 1.17(p).							
	Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account 13-4500, Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.							
X	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. <u>13-4500</u> , Order No. <u>2629-4005US4</u> . A DUPLICATE COPY OF THIS SHEET IS ATTACHED.							
Respectfully submitted, MORGAN & FINNEGAN, L.L.P.								
Dated: M	lay 18, 2	(Evelyn M. Kwon)						
Correspon	ndence A	_						
Dated: May 18, 2005 By: Evelyn M. Kwon Registration No. 54,246 Correspondence Address: MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, NY 10281-2101								

919765 v1 -3- EV 622479766 US



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY, DOCKET NO. 2629-4005US4	SERIAL NO. 09/970,477		
APPLICANT			
LORINCZ, A., et al.			
FILING DATE	GROUP ART UNIT		

1643

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

October 4, 2001

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT YES	TION
	0 502 994 B1	09/16/92	EPO				
	44 45 769 CL	09/11/95	DE			x	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.